CMS Should Have Required a Randomized Trial of F1CDx CMS Should Have Required a Randomized Trial of F1CDx
Authors give five reasons why CMS should have refrained from coverage of a 324-gene panel offered by Foundation Medicine in the absence of a randomized trial.Annals of Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news